Literature DB >> 30243617

Complement deposition on renal histopathology of patients with diabetic nephropathy.

Z-J Sun1, X-Q Li1, D-Y Chang1, S-X Wang1, G Liu1, M Chen2, M-H Zhao3.   

Abstract

AIMS: As the potential role of the complement system in diabetic nephropathy (DN) is increasingly reported, this study aimed to investigate C1q and C3c deposition as seen on renal histopathology, as well as its association with clinical and pathological parameters, in DN patients.
METHODS: Renal biopsy specimens from 161 DN patients were investigated using direct immunofluorescence, light, and electron microscopy. For direct immunofluorescence, staining for C1q and C3c on fresh-frozen renal tissue was performed immediately after biopsy. Complement deposition was defined as the presence of C1q or C3c of at least 1 + on a 0-4 + Scale. The association between complement deposition and clinicopathological data was also analyzed.
RESULTS: On direct immunofluorescence microscopy, C1q and C3c were detected in specimens from 44/161 (27.3%) and 89/161 (55.3%) patients, respectively. Regarding clinical data, patients with C1q deposition had a significantly higher level of urinary protein (7.25 ± 4.20 g/24 h vs. 4.97 ± 3.76 g/24 h; P < 0.01) and significantly lower estimated glomerular filtration rate (eGFR; 34.16 ± 25.21 mL/min/1.73 m2 vs. 51.17 ± 31.56 mL/min/1.73 m2, respectively; P < 0.01), whereas patients with vs. without C3c deposition had a significantly lower eGFR (40.09 ± 27.97 mL/min/1.73 m2 vs. 54.48 ± 32.49 mL/min/1.73 m2, respectively; P < 0.01). On renal histopathology, patients with C1q deposition had significantly higher Scores for interstitial fibrosis and tubular atrophy (IFTA), interstitial inflammation and vascular lesions (P < 0.01, P < 0.05 and P < 0.05, respectively), whereas patients with C3c deposition had significantly higher IFTA Scores and proportions of global sclerosis (P < 0.01 and P < 0.01, respectively).
CONCLUSION: Complement deposition of C1q and C3c on renal histopathology is associated with more severe kidney damage in patients with DN.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Complement; Diabetic nephropathy

Mesh:

Substances:

Year:  2018        PMID: 30243617     DOI: 10.1016/j.diabet.2018.08.011

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  16 in total

Review 1.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

2.  Is C1q nephropathy associated with a WDR19 gene mutation? A case report.

Authors:  K Kaynar; B Güvercin; Ö Güler; S Mungan; E Çağlayan
Journal:  Hippokratia       Date:  2021 Apr-Jun       Impact factor: 0.522

3.  Identification of Key Genes of Human Advanced Diabetic Nephropathy Independent of Proteinuria by Transcriptome Analysis.

Authors:  Fanghao Cai; Xujie Zhou; Yan Jia; Weijian Yao; Jicheng Lv; Gang Liu; Li Yang
Journal:  Biomed Res Int       Date:  2020-06-26       Impact factor: 3.411

4.  Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Authors:  Elisabetta Valoti; Marina Noris; Annalisa Perna; Erica Rurali; Giulia Gherardi; Matteo Breno; Aneliya Parvanova Ilieva; Ilian Petrov Iliev; Antonio Bossi; Roberto Trevisan; Alessandro Roberto Dodesini; Silvia Ferrari; Nadia Stucchi; Ariela Benigni; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Front Genet       Date:  2019-07-26       Impact factor: 4.599

5.  Serum Level of Complement C1q is Associated with Contrast-Associated Acute Kidney Injury in Patients Undergoing Emergency Percutaneous Coronary Intervention.

Authors:  Jun Tao; Chenglin Ye; Wen Dai; Di Li; Man Zhou; Yan Li
Journal:  J Inflamm Res       Date:  2021-12-24

6.  Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease.

Authors:  Qingmiao Lu; Qing Hou; Kai Cao; Xiaoli Sun; Yan Liang; Mengru Gu; Xian Xue; Allan Zijian Zhao; Chunsun Dai
Journal:  JCI Insight       Date:  2021-10-08

Review 7.  Innate immunity in diabetic kidney disease.

Authors:  Sydney C W Tang; Wai Han Yiu
Journal:  Nat Rev Nephrol       Date:  2020-01-15       Impact factor: 28.314

8.  Identification of C3 as a therapeutic target for diabetic nephropathy by bioinformatics analysis.

Authors:  ShuMei Tang; XiuFen Wang; TianCi Deng; HuiPeng Ge; XiangCheng Xiao
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

9.  Deficiency of C3a receptor attenuates the development of diabetic nephropathy.

Authors:  Xiao-Qian Li; Dong-Yuan Chang; Min Chen; Ming-Hui Zhao
Journal:  BMJ Open Diabetes Res Care       Date:  2019-11-15

Review 10.  The role of inflammation in diabetic kidney disease.

Authors:  Su Woong Jung; Ju-Young Moon
Journal:  Korean J Intern Med       Date:  2021-07-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.